Alivus Life Sciences Limited (ALIVUS) acquires 76% stake in IQGenX for INR 91.2 million, expanding its advanced formulation development capabilities.
Alivus Life Sciences Limited (NSE: ALIVUS) stock price gains 10% intraday, breaking out from its 6M resistance trendline..
Alivus Life Sciences Limited (ALIVUS) stock price gains 7% intraday, breaking out from its 6M resistance trendline. Current price at ₹1301.0.
Alivus Life Sciences Limited (ALIVUS) stock gains 5% intraday, bouncing back despite a weak 6-month trendline structure. Price at ₹1151.9.
Alivus Life Sciences Limited (ALIVUS) reports Q1 FY27 with 32% PAT growth, 25% margins, and revenue up 6.4% YoY.